A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma.
Leukemia
; 34(12): 3298-3309, 2020 12.
Article
in En
| MEDLINE
| ID: mdl-32409691
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
ADP-ribosyl Cyclase 1
/
Antibodies, Monoclonal, Humanized
/
Multiple Myeloma
/
Neoplasm Recurrence, Local
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Leukemia
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
Year:
2020
Document type:
Article
Affiliation country:
United States